Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis

Cameron, A, Ewen, M, Ross-Degnan, D, Ball, D, Laing, R · 2009 · The Lancet

Abstract

Background WHO and Health Action International (HAI) have developed a standardised method for surveying medicine prices, availability, affordability, and price components in low-income and middle-income countries. Here, we present a secondary analysis of medicine availability in 45 national and subnational surveys done using the WHO/HAI methodology.Methods Data from 45 WHO/HAI surveys in 36 countries were adjusted for inflation or deflation and purchasing power parity. International reference prices from open international procurements for generic products were used as comparators. Results are presented for 15 medicines included in at least 80% of surveys and four individual medicines.Findings Average public sector availability of generic medicines ranged from 29.4% to 54.4% across WHO regions. Median government procurement prices for 15 generic medicines were 1.11 times corresponding international reference prices, although purchasing efficiency ranged from 0.09 to 5.37 times international reference prices. Low procurement prices did not always translate into low patient prices. Private sector patients paid 9-25 times international reference prices for lowest-priced generic products and over 20 times international reference prices for originator products across WHO regions. Treatments for acute and chronic illness were largely unaffordable in many countries. In the private sector, wholesale mark-ups ranged from 2% to 380%, whereas retail mark-ups ranged from 10% to 552%. In countries where value added tax was applied to medicines, the amount charged varied from 4% to 15%.Interpretation Overall, public and private sector prices for originator and generic medicines were substantially higher than would be expected if purchasing and distribution were efficient and mark-ups were reasonable. Policy options such as promoting generic medicines and alternative financing mechanisms are needed to increase availability, reduce prices, and improve affordability.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(08)61762-6

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 8 references

Research works printed but not linked: 4

  1. Bala, 1998, Retail drug prices: the law of the jungle, Hainews, 100, 2
  2. Sagoo, 1999, HIV/AIDS: Improving access to essential drugs, Hainews, 110, 1
  3. Bala, 2000, Patents and prices, Hainews, 112, 1
  4. Madden, 2003, Comparing pilot survey results from different countries, Essential drugs monitor, 33, 19

Cited by

See all 928

Metadata

Authors
Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R.
Affiliations
  • World Health Organization (CH)
  • Health Action International (NL)
Corresponding author
Cameron, A
Venue
The Lancet
Publisher
Elsevier BV
Published
2009-01
Volume
373
Issue
9659
Pages
240-249
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2122047846
Cited by
928
References
8
Citations by year
2026: 29 · 2025: 30 · 2024: 52 · 2023: 56 · 2022: 47 · 2021: 81 · 2020: 71 · 2019: 70 · 2018: 57 · 2017: 69 · 2016: 48 · 2015: 57 · 2014: 64 · 2013: 67 · 2012: 39
FWCI
66.94
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • DigitalGeorgetown (Georgetown University Library) (submittedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
Keywords
drug pricing, drug availability, drug affordability, generic drugs, international reference prices, purchasing power parity
MeSH terms
Antacids, Anti-Bacterial Agents, Data Collection, Developing Countries, Health Services Accessibility, Humans, Reference Standards, Cluster Analysis, Drugs, Generic, Private Sector, Public Sector, Anti-Asthmatic Agents, Drugs, Essential, Developed Countries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(08)61762-6
The paper
Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2009). Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The Lancet. https://doi.org/10.1016/s0140-6736(08)61762-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.